GSK (GSK) Stock Overview
Engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
GSK Community Fair Values
Create NarrativeSee what 313 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
DA
Community Contributor
GSK: March Madness Lineup
March Madness is here, or so they say on the basketball courts. But Marchs madness is slowly moving off to more than just the courts.
View narrativeUK£78
FV
76.2% undervalued intrinsic discount49.03%
Revenue growth p.a.
945
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
25users have followed this narrative
Pharmaceuticals & Biotech opportunity
LO
Fair Value from
US$7.675.4% undervalued intrinsic discount
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeGSK plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£18.59 |
| 52 Week High | UK£22.82 |
| 52 Week Low | UK£12.89 |
| Beta | 0.30 |
| 1 Month Change | -11.33% |
| 3 Month Change | -15.45% |
| 1 Year Change | 36.25% |
| 3 Year Change | 28.63% |
| 5 Year Change | 9.86% |
| Change since IPO | 77.42% |
Recent News & Updates
Narrative Update • May 02
GSK: Expanding Respiratory And Vaccine Portfolio Approvals Will Support Future Upside
Analysts have lifted their GSK price target by £1 to £27.50, citing a slightly lower long term revenue growth path, a reduced profit margin assumption and a higher future P/E multiple that together keep fair value unchanged overall. Analyst Commentary Recent Street research around GSK has tilted more constructive, with several bullish analysts lifting price targets and pointing to drivers that they see as supportive of the current valuation framework.
New Narrative • Apr 26
GSK plc (GSK): The Vaccine Sentinel Faces a Critical Pivot Toward Specialty Mastery
GSK plc (GSK) , the global vanguard of vaccine innovation and high-science biopharmaceuticals, enters the weekend of Sunday, April 26, 2026 , in a state of disciplined transformation. The company is set to release its Q1 2026 earnings report on Wednesday, April 29, 2026, before the London market opens.Recent updates
Narrative Update • May 02
GSK: Expanding Respiratory And Vaccine Portfolio Approvals Will Support Future Upside
Analysts have lifted their GSK price target by £1 to £27.50, citing a slightly lower long term revenue growth path, a reduced profit margin assumption and a higher future P/E multiple that together keep fair value unchanged overall. Analyst Commentary Recent Street research around GSK has tilted more constructive, with several bullish analysts lifting price targets and pointing to drivers that they see as supportive of the current valuation framework.New Narrative • Apr 26
GSK plc (GSK): The Vaccine Sentinel Faces a Critical Pivot Toward Specialty Mastery
GSK plc (GSK) , the global vanguard of vaccine innovation and high-science biopharmaceuticals, enters the weekend of Sunday, April 26, 2026 , in a state of disciplined transformation. The company is set to release its Q1 2026 earnings report on Wednesday, April 29, 2026, before the London market opens.Narrative Update • Apr 18
GSK: Respiratory And Vaccine Portfolio Execution Will Support Higher Future Upside
Analysts have lifted their GSK price targets by £100 to £350, or to around £17.00 to £19.00 per share, citing slightly higher assumptions for revenue growth and profit margins alongside a modestly lower future P/E multiple in updated models. Analyst Commentary Recent research on GSK has tilted more constructive, with several bullish analysts revisiting their models and adjusting price targets in light of updated assumptions on revenue growth, profitability and valuation multiples.
Narrative Update • Apr 03
GSK: Limited Pipeline Readouts Will Continue To Cap Future Multiple Repricing
GSK's analyst price target has moved higher by £100, with analysts pointing to slightly stronger long term revenue growth and profit margin assumptions, alongside modestly lower future P/E expectations. Analyst Commentary Recent research on GSK reflects a mix of higher price targets and ongoing caution around the company’s execution and growth profile.Narrative Update • Mar 19
GSK: Upgraded Fair Value Will Rely On Expanding Respiratory And Vaccine Portfolio
Analysts have raised the fair value estimate for GSK from £23.63 to £27.50. They attribute this change to recent upward revisions to Street price targets, along with updated assumptions that include slightly lower revenue growth, a higher discount rate, modestly stronger profit margins, and a marginally higher future P/E.Narrative Update • Mar 05
GSK: Limited Pipeline Visibility Will Continue To Restrain Future Multiple Expansion
The analyst price target for GSK has been raised by a triple digit number of pence across several recent reports, with analysts pointing to updated views on the pipeline and profitability as key reasons for the revised pound price range. Analyst Commentary Recent Street research on GSK shows a mixed backdrop, with several price target increases sitting alongside cautious views on the company’s execution and growth profile.Narrative Update • Feb 19
GSK: Limited Late Stage Data Will Restrain Future Multiple Expansion
GSK's updated analyst price target edges higher by £0.15 to £14.70, as analysts factor in slightly adjusted growth assumptions, a modestly higher discount rate, firmer profit margins, and a lower future P/E multiple. This is reflected in recent target increases from Citi, BofA, TD Cowen, Deutsche Bank, and Morgan Stanley.Analysis Article • Feb 13
GSK (LON:GSK) Will Pay A Larger Dividend Than Last Year At £0.18
GSK plc ( LON:GSK ) has announced that it will be increasing its dividend from last year's comparable payment on the...Analysis Article • Feb 11
Statutory Profit Doesn't Reflect How Good GSK's (LON:GSK) Earnings Are
When companies post strong earnings, the stock generally performs well, just like GSK plc's ( LON:GSK ) stock has...
Narrative Update • Feb 05
GSK: Limited Pipeline Readouts And CEO Constraints Will Pressure Long Term Returns
Analysts have nudged their fair value estimate for GSK slightly higher to £18.83 from £18.73, reflecting updated assumptions around long term revenue growth, profit margins and a modestly higher future P/E multiple following recent price target revisions and mixed rating changes across the Street. Analyst Commentary Street research on GSK has been mixed, with some firms adjusting price targets higher while others are more cautious on the company’s pipeline and room for operational change.Narrative Update • Jan 21
GSK: Vaccine Franchise And Pipeline Execution Will Shape Balanced Long Term Returns
The analyst price target for GSK has been nudged higher to reflect a slightly increased fair value estimate of £18.73, with analysts pointing to recent target raises, a modest adjustment to long term P/E assumptions, and ongoing debate around pipeline visibility and profitability. Analyst Commentary Recent research on GSK reflects a mix of optimism around valuation support and price targets, alongside clear concern about execution risks and pipeline visibility.Narrative Update • Jan 07
GSK: Limited Pipeline Readouts Will Cap Multiple Expansion Potential
Analysts have lifted their implied fair value for GSK from £11.20 to £14.55 per share, while trimming long term revenue growth and margin assumptions. They have also assigned a higher future P/E in light of recent price target moves and concerns about limited pipeline readouts and the new CEO's room to maneuver.Narrative Update • Dec 13
GSK: Vaccine Strength And Manufacturing Investments Will Drive Balanced Returns Amid Policy Uncertainty
The analyst price target for GSK has inched higher to approximately $18.64 from about $18.27 as analysts factor in slightly stronger long-term revenue growth and margins, supported by a more constructive outlook for large-cap pharma fundamentals. Analyst Commentary Recent Street research on GSK reflects a cautiously constructive stance, with modest target price increases signaling confidence in the company’s execution on its pipeline and margin profile but limited enthusiasm for the current valuation.Narrative Update • Nov 28
GSK: Manufacturing Investments And Policy Changes Will Drive Performance Amid Stable Market Conditions
The analyst price target for GSK has been raised from 1,400 GBp to 1,500 GBp. This reflects a moderate increase in fair value estimates as analysts cite stable margins and steady revenue expectations. Analyst Commentary Analyst reaction to the updated GSK price target has been mixed, reflecting a range of perspectives on the company's valuation, growth opportunities, and business execution.Narrative Update • Nov 14
GSK: Margin Outlook and Digital Expansion Will Shape Performance Amid Industry Shifts
GSK's analyst price target has been raised from £14.00 to £15.00 per share. This change reflects analysts' updated expectations for higher fair value, improved growth prospects, and better profit margins supported by recent research commentary.Narrative Update • Oct 30
GSK: Technology Adoption And U.S. Investment Will Shape Sector Positioning Amid Policy Shifts
Analysts have raised their fair value estimate for GSK to $17.36 from $16.63. They cite higher profit margin expectations and improved sector sentiment following significant technology rollouts and favorable policy signals.Narrative Update • Oct 16
Global Vaccine Demand And Specialty Medicines Will Expand Future Opportunities
Analysts have increased their fair value estimate for GSK from $16.51 to $16.63, citing expectations for slightly improved profit margins as well as ongoing advancements in the company's operational efficiency. Analyst Commentary Recent Street research provides a nuanced perspective on GSK's prospects, revealing both renewed optimism and underlying caution from market observers.Analysis Article • Sep 19
Market Cool On GSK plc's (LON:GSK) Earnings
It's not a stretch to say that GSK plc's ( LON:GSK ) price-to-earnings (or "P/E") ratio of 17.3x right now seems quite...Shareholder Returns
| GSK | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -3.6% | -1.2% | 2.4% |
| 1Y | 36.3% | 23.0% | 21.7% |
Return vs Industry: GSK exceeded the UK Pharmaceuticals industry which returned 23% over the past year.
Return vs Market: GSK exceeded the UK Market which returned 21.7% over the past year.
Price Volatility
| GSK volatility | |
|---|---|
| GSK Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: GSK has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: GSK's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 66,841 | Luke Miels | www.gsk.com |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.
GSK plc Fundamentals Summary
| GSK fundamental statistics | |
|---|---|
| Market cap | UK£74.19b |
| Earnings (TTM) | UK£5.83b |
| Revenue (TTM) | UK£32.78b |
12.7x
P/E Ratio2.3x
P/S RatioIs GSK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSK income statement (TTM) | |
|---|---|
| Revenue | UK£32.78b |
| Cost of Revenue | UK£8.89b |
| Gross Profit | UK£23.89b |
| Other Expenses | UK£18.06b |
| Earnings | UK£5.83b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.46 |
| Gross Margin | 72.87% |
| Net Profit Margin | 17.78% |
| Debt/Equity Ratio | 109.7% |
How did GSK perform over the long term?
See historical performance and comparisonDividends
3.9%
Current Dividend Yield46%
Payout RatioDoes GSK pay a reliable dividends?
See GSK dividend history and benchmarks| GSK dividend dates | |
|---|---|
| Ex Dividend Date | May 14 2026 |
| Dividend Pay Date | Jul 09 2026 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 61 days |
Does GSK pay a reliable dividends?
See GSK dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 10:42 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GSK plc is covered by 48 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |
| Emily Field | Barclays |